BusinessActinium Pharmaceuticals to Present at BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 9, 2017, 12:01 PM UTC
BusinessActinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple MyelomaBy Nasdaq OMXFeb 7, 2017, 1:01 PM UTC
BusinessActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative NeoplasmsBy Nasdaq OMXJan 24, 2017, 12:01 PM UTC
BusinessActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative NeoplasmsBy Nasdaq OMXJan 24, 2017, 12:01 PM UTC
BusinessActinium Announces Participation in Three Upcoming Hematology EventsBy Nasdaq OMXJan 20, 2017, 12:00 PM UTC
BusinessActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical OfficerBy Nasdaq OMXJan 18, 2017, 1:01 PM UTC
BusinessActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical OfficerBy Nasdaq OMXJan 18, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 ConferenceBy Nasdaq OMXJan 10, 2017, 12:00 PM UTC
